Discover essential updates from Amicus Therapeutics, Inc. in their 8-K report filed on February 21, 2025. Get insights on corporate events, stock performance, and compliance.
Discover key insights from Amicus Therapeutics' 2024 10-K Report, detailing revenue growth, financial health, and investment strategies. Current stock recommendation: Hold.
Explore Amicus Therapeutics' 8-K filing dated February 19, 2025, detailing significant corporate events. Essential for investors tracking FOLD's performance on NASDAQ.
Explore Amicus Therapeutics' latest 8-K filing detailing significant updates on operations, stock details, and financial insights. Stay informed on ticker FOLD.